Extension to the MAGNIFY MS Trial on Mavenclad® (Magnify MS Extension)
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- 256
Summary
- Conditions
- Multiple Sclerosis
- Type
- Interventional
- Phase
- Phase 4
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentIntervention Model Description: Open label, single arm, exploratory, multicenter, 2-year, Phase IV extension study.Masking: None (Open Label)Primary Purpose: Other
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT04783935
- Collaborators
- Not Provided
- Investigators
- Study Director: Medical Responsible Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Get Well Soon